全文获取类型
收费全文 | 150篇 |
免费 | 17篇 |
专业分类
儿科学 | 3篇 |
妇产科学 | 1篇 |
基础医学 | 38篇 |
临床医学 | 23篇 |
内科学 | 56篇 |
外科学 | 5篇 |
预防医学 | 1篇 |
药学 | 33篇 |
肿瘤学 | 7篇 |
出版年
2021年 | 5篇 |
2020年 | 1篇 |
2019年 | 10篇 |
2018年 | 6篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 6篇 |
2014年 | 10篇 |
2013年 | 5篇 |
2012年 | 11篇 |
2011年 | 13篇 |
2010年 | 7篇 |
2009年 | 4篇 |
2008年 | 2篇 |
2007年 | 6篇 |
2006年 | 3篇 |
2004年 | 3篇 |
2003年 | 4篇 |
2002年 | 4篇 |
2001年 | 9篇 |
2000年 | 9篇 |
1999年 | 7篇 |
1998年 | 1篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 5篇 |
1988年 | 5篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
排序方式: 共有167条查询结果,搜索用时 640 毫秒
91.
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review 总被引:1,自引:0,他引:1
Second-generation histamine H(1) receptor antagonists were developed to provide efficacious treatment of allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) while decreasing adverse effects associated with first-generation agents. When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levocetirizine - many pharmacological and clinical criteria must be considered. Most importantly, these elements should not be evaluated separately but, rather, as parts of a puzzle that create a whole picture. As a class, second-generation antihistamines are highly selective for the H(1) receptor. Some bind to it with high affinity, although there is marked heterogeneity among the various compounds. They have a limited effect on the CNS, and clinical studies have noted almost no significant drug-drug interactions in the agents studied. No major cytochrome P450 inhibition has been reported with desloratadine, fexofenadine and levocetirizine, and the bioavailability of desloratadine is minimally affected by drugs interfering with transporter molecules. Of the second-generation antihistamines, desloratadine has the greatest binding affinity for the H(1) receptor. The use of desloratadine, fexofenadine and levocetirizine is not associated with clinically relevant antimuscarinic effects. Desloratadine and fexofenadine do not impair cognitive or psychomotor functioning and are comparable with placebo in terms of somnolence. Based on these pharmacological characteristics, as well as clinical endpoints such as symptom scores, quality-of-life surveys, inflammatory cell counts and investigators' global evaluations, we conclude that desloratadine, fexofenadine and levocetirizine are all efficacious treatments for AR and CIU. However, differences among the antihistamines in relation to a lack of significant interaction with drug transporter molecules and somnolence in excess of placebo may provide some advantages for the overall profile of desloratadine compared with fexofenadine and levocetirizine. 相似文献
92.
Devillier P 《Clinical therapeutics》2007,29(12):2774-5, author reply 2775-6
93.
94.
Anne Wanquet Stephania Bramanti Samia Harbi Sabine Fürst Faezeh Legrand Catherine Faucher Angela Granata Boris Calmels Claude Lemarie Christophe Picard Christian Chabannon Pierre-Jean Weiller Luca Castagna Didier Blaise Raynier Devillier 《Biology of blood and marrow transplantation》2018,24(3):549-554
We evaluated the impact of unidirectional donor versus recipient killer cell immunoglobulin-like receptor (KIR)–ligand mismatch (KIR-Lmm) on the outcomes of T cell–replete haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) in a cohort of 144 patients treated for various hematologi diseases. We separately analyzed 81 patients in complete remission (CR group) and 63 with active disease (no CR group) at the time of Haplo-SCT. One-third of patients in each group had KIR-Lmm. In the no CR group, KIR-Lmm was associated with a significantly lower incidence of relapse (hazard ratio, .21; P?=?.013) and better progression-free survival (hazard ratio, .42; P?=?.028), with no significant increase in graft-versus-host disease incidence or nonrelapse mortality. In contrast, in the CR group no benefit of KIR-Lmm was observed. Our results encourage considering KIR-Lmm as an additional tool to improve donor selection for T cell–replete Haplo-SCT with PT-Cy, especially in patients with high-risk diseases. 相似文献
95.
96.
The known efficacy of fluticasone propionate in adults, comparable at half-dosage of corticosteroids has been validated by the market authorization (MA) and by the national and international guidelines for beclomethasone. This could be partly explained by its pharmacological properties, affinity for glucocorticosteroid receptors, lung deposition and lipophilicity. The limited systemic adverse events is due to its low bioavailability, optimal hepatic clearance, high plasma protein binding. The efficacy in asthmatic children has been confirmed in clinical studies showing a "plateau" efficacy between 100 and 200 microg/d for the majority of children. Most children are controlled by such dosages: the added value of increasing posology on asthma control exists but is small. A high off-label posology does not allow more quickly asthma control and therefore is not justified. A twice daily dosing is more efficient, particularly for initiation of maintenance therapy, than a once daily dosing. A literature survey confirms that, at MA recommended daily doses in children (100-200 microg), fluticasone propionate has no clinically significant effect either on hypothalamic-pituitary-adrenal (HPA) axis (basal function or stimulation tests), bone or growth velocity. However, high daily doses (higher to 500 microg/day) for long periods expose to systemic adverse effects with measurable consequences on growth rate, bone density (decreasing biochemical makers of bone formation) and HPA function. Several cases of adrenal insufficiency that may have led to acute adrenal crisis have been reported in 4- to 10-year-old children receiving fluticasone propionate in doses between 500 to 2000 microg daily. In case of surgery or infection, a preventive treatment of adrenal insufficiency with hydrocortisone should be proposed for children treated for more than 6 months with such high daily doses. Such children need definitely an advice from paediatricians specialized in chest diseases as well as in endocrinology. It is important to recall that the clinical benefit of daily doses of inhaled corticosteroids higher than recommended is low and that the good use of inhaled corticosteroids particularly in children lays on the careful search of the minimal efficient daily doses. 相似文献
97.
Cristoforo Incorvaia Mona Al-Ahmad Ignacio J. Ansotegui Stefania Arasi Claus Bachert Catherine Bos Jean Bousquet Andrzéj Bozek Davide Caimmi Moises A. Calderón Thomas Casale Adnan Custovic Frédéric De Blay Pascal Demoly Philippe Devillier Alain Didier Alessandro Fiocchi Adam T. Fox Philippe Gevaert Maximiliano Gomez Enrico Heffler Natalia Ilina Carla Irani Marek Jutel Efstrathios Karagiannis Ludger Klimek Piotr Kuna Robin O'Hehir Oxana Kurbacheva Paolo M. Matricardi Mario Morais-Almeida Ralph Mosges Natalija Novak Yoshitaka Okamoto Petr Panzner Nikolaos G. Papadopoulos Hae-Sim Park Giovanni Passalacqua Ruby Pawankar Oliver Pfaar Peter Schmid-Grendelmeier Silvia Scurati Miguel Tortajada-Girbés Carmen Vidal J. Christian Virchow Ulrich Wahn Margitta Worm Petra Zieglmayer Giorgio W. Canonica 《Allergy》2021,76(4):1041-1052
The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes. 相似文献
98.
Bomsel M Tudor D Drillet AS Alfsen A Ganor Y Roger MG Mouz N Amacker M Chalifour A Diomede L Devillier G Cong Z Wei Q Gao H Qin C Yang GB Zurbriggen R Lopalco L Fleury S 《Immunity》2011,34(2):269-280
Human immunodeficiency virus (HIV)-1 is mainly transmitted mucosally during sexual intercourse. We therefore evaluated the protective efficacy of a vaccine active at mucosal sites. Macaca mulatta monkeys were immunized via both the intramuscular and intranasal routes with an HIV-1 vaccine made of gp41-subunit antigens grafted on virosomes, a safe delivery carrier approved in humans with self-adjuvant properties. Six months after 13 vaginal challenges with simian-HIV (SHIV)-SF162P3, four out of five vaccinated animals remained virus-negative, and the fifth was only transiently infected. None of the five animals seroconverted to p27gag-SIV. In contrast, all 6 placebo-vaccinated animals became infected and seroconverted. All protected animals showed gp41-specific vaginal IgAs with HIV-1 transcytosis-blocking properties and vaginal IgGs with neutralizing and/or antibody-dependent cellular-cytotoxicity activities. In contrast, plasma IgGs totally lacked virus-neutralizing activity. The protection observed challenges the paradigm whereby circulating antiviral antibodies are required for protection against HIV-1 infection and may serve in designing a human vaccine against HIV-1-AIDS. 相似文献
99.
100.